B O O K - American College of Rheumatology

ACR/ARHP Poster Session C
CA, 29 University of Birmingham, Birmingham, United Kingdom,
30
University of Manitoba, Winnipeg, MB, Canada, 31 University
of North Carolina at Chapel Hill, Chapel Hill, NC, 32 University of
Toronto Lupus Clinic, Toronto Western Hospital, 33 University of
Toronto Lupus Clinic, Toronto Western Hospital, Toronto, ON,
Canada, 34 West Penn Allegheny Health System, Pittsburgh, PA.
1878. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-
2K) Responder Index (SRI)-50: A Valid Index for Measuring
Improvement in Disease Activity. Zahi Touma 2 , Dafna D.
Gladman 1 , Dominique Ibañez 2 and Murray B. Urowitz 2 , 1 Toronto
Western Hospital, Toronto, ON, Canada, 2 University of Toronto
Lupus Clinic, Toronto Western Hospital, Toronto, ON, Canada.
1879. The Relative Importance of Current Versus Past Use of
Medication in Excess Rates of Adverse Cardiovascular Events
among Patients with SLE. Michelle A. Petri 1 and Laurence
S. Magder 2 , 1 Timonium, MD, 2 Department of Epidemiology
and Preventive Medicine, University of Maryland School of
Medicine, Baltimore, MD.
1880. Validation of CLASI Scale with Lupus Disease Activity, Damage,
Body Image and Quality of Life. Meenakshi Jolly 1 , Rachel A.
Mikolaitis 3 , Thomas F. Cash 2 and Joel A. Block 2 , 1 Rush University
Medical Center, Chicago, IL, 2 Rush University Medical Center,
Chicago, IL, 3 Rush University Medical Center.
1881. Validity of the ACR Criteria and SLICC Proposed Criteria for the
Diagnosis and Classification of Systemic Lupus Erythematosus.
Felipe Rodriguez-García 2 , Karina Santana- de Anda 2 , Ali Duarte-
García 1 , Virginia Pascual-Ramos 2 , Gabriela Hernández-Medina 2 ,
Tatiana Rodríguez-Reyna 2 and Jorge Sanchez-Guerrero 3 ,
1
Instituto Nacional ce Ciencias Medicas y Nutricion Salvador
Zubiran, 2 Instituto Nacional de Ciencias Medicas y Nutricion
Salvador Zubiran, 3 Instituto Nacional de Ciencias Medicas y
Nutricion Salvador Zubiran, Mexico.
1882. Work Disability, Lost Productivity and Associated Risk Factors
in Patients Diagnosed with Systemic Lupus Erythematosus
(SLE). Tammy O. Utset 5 , Barbara M. Segal 6 , Laura Trupin 4 , Sarika
Ogale 1 , Ellen Herberich 2 and Kenneth C. Kalunian 3 , 1 Genentech,
2
Harris Interactive, 3 UCSD School of Medicine, La Jolla, CA,
4
University of California, San Francisco, 5 University of Chicago,
Chicago, IL, 6 University of Minnesota, Minneapolis, MN.
Sjögren’s Syndrome
1883. Activation of Innate Immunity and Sjögren’s Syndrome
Development. Seshagiri Rao Nandula 1 , Yogesh M. Scindia 2 ,
Harini Bagavant 1 and Umesh S. Deshmukh 2 , 1 University of
Virginia, Charlottesville, VA, 2 University of Virginia.
1884. Anticentromere Antibodies (ACA)-Positive Systemic Sclerosis
(SSc) Patients with Sjögren’s Syndrome: A Distintict Subset at
High Risk of Lymphoma. Chiara Baldini, Sara Grossi, Alessandra
Della Rossa, Nicoletta Luciano, Marica Doveri, Antonio
Gaetano Tavoni and Stefano Bombardieri, Rheumatology Unit,
Department of Internal Medicine, University of Pisa, Italy.
1885. Association between Lymphotoxin Alpha Genetic Variants
and Primary Sjögren’s Syndrome in Scandinavian Samples.
Anne Isine Bolstad 1 , Stephanie Le Hellard 2 , Gudlaug Thora
Kristjansdottir 4 , Gunnel Nordmark 4 , Lilian Vasaitis 8 , Marika
Kvarnström 6 , Christopher Sjöwall 13 , Svein Joar Auglænd
Johnsen 9 , Per Eriksson 12 , Roald Omdal 10 , Johan G. Brun 5 , Marie
Wahren-Helenius 6 , Elke Theander 7 , Ann-Christine Syvänen 3 ,
Lars Rönnblom 4 and Roland Jonsson 11 , 1 Department of
Clinical Dentistry-Periodontics, University of Bergen, Bergen,
Norway, 2 Department of Clinical Medicine, University of
Bergen, Center of Medical Genetics and Molecular Medicine,
Haukeland University Hospital, Bergen, Norway, 3 Department
of Medical Sciences, Molecular Medicine, Uppsala University,
Uppsala, Sweden, 4 Department of Medical Sciences, Section
of Rheumatology, Uppsala University, Uppsala, Sweden,
5
Department of Medicine, Section of Rheumatology, University
of Bergen, Bergen, Norway, 6 Karolinska Institutet, Stockholm,
Sweden, 7 Malmö University Hospital, Malmö, Sweden, 8 Section
of Rheumatology, Uppsala University, Uppsala, Sweden,
9
Stavanger University Hospital, Stavanger, Norway, 10 Stavanger
University Hospital, Stavanger, Norway 11 The Gade Institute,
University of Bergen, Bergen, Norway, 12 University Hospital
Linköping, Sweden, Linköping, Sweden, 13 University Hospital,
Linköping, Linköping, Sweden.
1886. B-Cell Profiling Using Multi-Color Flow Cytometry as Biomarker
of Disease Progression in Primary Sjogren’s Syndrome
(pSS). Mustimbo Roberts 2 , Craig Maguire 3 , Alex Rosenberg 3 ,
Andreea Coca 2 , Jennifer H. Anolik 1 and Iñaki Sanz 2 , 1 University
of Rochester, Rochester, NY, 2 University of Rochester Medical
Center, Rochester, NY, 3 University of Rochester Medical Center.
1887. Best Scintigraphic Measures of Parotid Gland Dysfunction in
Sjogren’s Syndrome. Anthony Keyes 4 , Julius Birnbaum 2 , John
Petronis 1 and Alan N. Baer 3 , 1 Johns Holins University School of
Medicine, 2 Johns Hopkins University, Baltimore, MD, 3 Johns
Hopkins University, Baltimore, MD, 4 Johns Hopkins University
School of Medicine.
1888. Clinical and Immunological Profile of Patients with Primary
Sjogren Syndrome Who Developed B-Cell Lymphoma. Analysis
of 1010 Spanish Patients (The GEMESS Cohort). Manuel
Ramos-Casals 3 , Roser Solans 11 , Jose Rosas 6 , Maria Teresa
Camps 2 , Antonio Gil 9 , Javier Del-Pino 10 , Carmen Hidalgo 12 ,
Jaime Calvo 4 , Maria Luisa Mico 8 , Roberto Perez-Alvarez 7 , Rafael
Belenguer 1 and Lucio Pallares 5 , 1 Hospital 9 d’Octubre, València,
Spain, 2 Hospital Carlos Haya, Malaga, Spain, 3 Hospital Clinic,
Barcelona, Spain, 4 Hospital de Sierrallana, Torrelavega, Spain,
5
Hospital de Son Dureta, Palma de Mallorca, Spain, 6 Hospital
de Vilajoyosa, Alicante, Spain, 7 Hospital do Meixoeiro, Vigo,
Spain, 8 Hospital La Fe, Valencia, Spain, 9 Hospital La Paz, Madrid,
Spain, 10 Hospital Universitario de Salamanca, Salamanca, Spain,
11
Hospital Vall d’Hebron, Barcelona, Spain, 12 Hospital Virgen de
las Nieves, Granada, Spain.
1889. Clonal Analysis of Ig-Expressing Cells in Salivary Glands
of Primary Sjögren’s Syndrome Patients after Anti-CD20
Treatment. Nishath Hamza 3 , Hendrika Bootsma 4 , Rodney
P. E. Pollard 2 , Jiska M. Meijer 2 , Fred K. L. Spijkervet 2 , Arjan
Vissink 2 , Hans G. M. Burgerhof 5 , Frans G. M. Kroese 1 , Cees G.
M. Kallenberg 4 and Nicolaas A. Bos 1 , 1 Dept. of Cell Biology,
Immunology Section, University Medical Center Groningen,
University of Groningen, Groningen, The Netherlands,
2
Dept. of Oral and Maxillofacial Surgery, University Medical
Center Groningen, University of Groningen, Groningen, The
Netherlands, 3 Dept. of Rheumatology and Clinical Immunology
& Dept. of Cell Biology, Immunology Section, University
Medical Center Groningen, University of Groningen, Groningen,
The Netherlands, 4 Dept. of Rheumatology and Clinical
Immunology, University Medical Center Groningen, University
of Groningen, Groningen, The Netherlands, 5 University Medical
Center Groningen, University of Groningen, Groningen, The
Netherlands.
2010 Program Book 265